`
`
`
`
`
`
`
`
`DEPARTMENT OF HEALTH AND HUMAN SERVICES
`
`
`
`
`
` NDA 022341/S-025
`
`
`
`
`
`
`
`
`
`
`
` Food and Drug Administration
`
` Silver Spring MD 20993
`
`
`
`
`
`SUPPLEMENT APPROVAL
`
`
`
` Novo Nordisk, Inc.
`
`
` Attention: Michelle Thompson
` Senior Director, Regulatory Affairs
`
` P.O. Box 846, 800 Scudders Mill Road
`
`
` Plainsboro, NJ 08536
`
`
`
`
`Dear Ms. Thompson:
`
`
`
`
`
`
`
`Please refer to your Supplemental New Drug Application (sNDA) dated and received
`
`
`June 23, 2015, and your amendments, submitted under section 505(b) of the Federal Food, Drug,
`
`
`
`
`
`and Cosmetic Act (FDCA) for Victoza (liraglutide injection).
`
`
`
`
`
`
`This Prior Approval supplemental new drug application provides for the following changes:
`
`
`
`
`• A revised Package Insert (PI) with proposed changes to several sections based on the
`
`
`
`results from Trial NN2211-3916, which was a 26-week double-blind placebo-controlled,
`
`
`
`randomized, multicenter, multinational, parallel-group trial which assessed the safety and
`
`
`efficacy of liraglutide in subjects with type 2 diabetes and moderate renal impairment;
`• Changes to Section 6 Adverse Reactions to provide for alignment of safety information
`
`
`from the Saxenda® PI (NDA 206321, approved December 23, 2014);
`
`
`• Consolidated adverse reaction tables in Section 6 Adverse Reactions.
`
`
`
`
`
`
`APPROVAL & LABELING
`
`
`
`We have completed our review of this supplemental application, as amended. It is approved,
`
`effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling
`
`text.
`
`
`
`CONTENT OF LABELING
`
`
`As soon as possible, but no later than 14 days from the date of this letter, submit the content of
`
`
`labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA
`
`
`
`automated drug registration and listing system (eLIST), as described at
`
`http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content
`
`
`of labeling must be identical to the enclosed labeling, with the addition of any labeling changes
`
`
`
`
`in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes
`not included in the enclosed labeling.
`
`
`
`Reference ID: 3920460
`
`
`
`
`
`
` NDA 022341/S-025
` Page 2
`
`
`
` Information on submitting SPL files using eList may be found in the guidance for industry titled
`
`
`
` “SPL Standard for Content of Labeling Technical Qs and As at
`http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/U
`CM072392.pdf
`
`
`The SPL will be accessible from publicly available labeling repositories.
`
`
`Also within 14 days, amend all pending supplemental applications that includes labeling changes
`
`
`
`
`for this NDA, including CBE supplements for which FDA has not yet issued an action letter,
`
`with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the
`
`
`
`
`
`changes approved in this supplemental application, as well as annual reportable changes and
`
`annotate each change. To facilitate review of your submission, provide a highlighted or marked-
`
`up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy
`
`should provide appropriate annotations, including supplement number(s) and annual report
`
`
`
`
`
`
`date(s).
`
`
`REQUIRED PEDIATRIC ASSESSMENTS
`
`
`Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new
`
`
`active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of
`
`
`administration are required to contain an assessment of the safety and effectiveness of the
`product for the claimed indication(s) in pediatric patients unless this requirement is waived,
`
`
`
`deferred, or inapplicable.
`
`
`Because none of these criteria apply to your application, you are exempt from this requirement.
`
`PROMOTIONAL MATERIALS
`
`
`
`You may request advisory comments on proposed introductory advertising and promotional
`
`labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory
`
`
`
`comments, (2) the proposed materials in draft or mock-up form with annotated references, and
`
`(3) the package insert(s) to:
`
`
`
`
`
`OPDP Regulatory Project Manager
`
`
`Food and Drug Administration
`
`Center for Drug Evaluation and Research
`
`Office of Prescription Drug Promotion (OPDP)
`
`5901-B Ammendale Road
`
`Beltsville, MD 20705-1266
`
`
`
`
`Alternatively, you may submit a request for advisory comments electronically in eCTD format.
`
`
`
`For more information about submitting promotional materials in eCTD format, see the draft
`Guidance for Industry (available at:
`http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/U
`CM443702.pdf ).
`
`
`
`Reference ID: 3920460
`
`
`
`
`
`
` NDA 022341/S-025
` Page 3
`
`
`
`
`
`You must submit final promotional materials and package insert(s), accompanied by a Form
`
`
`
`
`
`
`FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form
`
`
`FDA 2253 is available at
`http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf.
`Information and Instructions for completing the form can be found at
`
`http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For
`
`more information about submission of promotional materials to the Office of Prescription Drug
`
`
`Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.
`
`
`REPORTING REQUIREMENTS
`
`
`We remind you that you must comply with reporting requirements for an approved NDA
`
`
`(21 CFR 314.80 and 314.81).
`
`
`
`If you have any questions, call Marisa Petruccelli, Regulatory Project Manager, at
`
`
`(240) 402-6147.
`
`
`
`Sincerely,
`
`
`{See appended electronic signature page}
`
`
`
`Jean-Marc Guettier, M.D.
`
`
`Director
`
`Division of Metabolism and Endocrinology Products
`
`Office of Drug Evaluation II
`
`Center for Drug Evaluation and Research
`
`
`
`ENCLOSURES:
`
`Package Insert
`
`Medication Guide (version approved on March 9, 2015)
`
`
`Instructions for Use (version approved on February 25, 2015)
`
`
`
`
`Reference ID: 3920460
`
`
`
`---------------------------------------------------------------------------------------------------------
`This is a representation of an electronic record that was signed
`electronically and this page is the manifestation of the electronic
`signature.
`---------------------------------------------------------------------------------------------------------
`/s/
`----------------------------------------------------
`
`JEAN-MARC P GUETTIER
`04/22/2016
`
`Reference ID: 3920460
`
`